Synergistic seizure reduction in patient with persistently elevated N-desmethylclobazam levels, CYP450 genetic polymorphism, and responsive neurostimulator targeting centromedian nuclei of bilateral thalami

Clobazam (CLB) and cenobamate (CNB) are commonly used antiseizure medications (ASMs) in the treatment of patients with drug-resistant epilepsy (DRE). However, concomitant use of these two ASMs may lead to significant treatment-related adverse events (TRAE). Furthermore, these TRAE may be exacerbated...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Andrew Zillgitt, David E Burdette, Atheel Yako, Revati Rashingkar, Ashleigh Terrell, Sydney Jacobs, Michael D Staudt
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Elsevier 2025-09-01
Colecção:	Epilepsy & Behavior Reports
Assuntos:	Clobazam Cenobamate Pharmacogenetics Idiopathic generalized epilepsy Responsive neurostimulator
Acesso em linha:	http://www.sciencedirect.com/science/article/pii/S2589986425000590
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!